Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at ...

Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...

The stock's fall snapped a five-day winning streak.

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $94.11 which represents a decrease of $-0.30 or -0.32% from the prior close of $94.41. The stock opened at $93.43 and touched a low of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $93.95 which represents a slight increase of $0.55 or 0.59% from the prior close of $93.4. The stock opened at $93 and touched ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...